Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023

BUY
$2.23 - $3.1 $942,578 - $1.31 Million
422,681 New
422,681 $1.28 Billion
Q4 2022

Feb 14, 2023

BUY
$1.91 - $2.85 $799,386 - $1.19 Million
418,527 New
418,527 $975,000
Q3 2022

Nov 14, 2022

BUY
$1.88 - $2.88 $57,550 - $88,162
30,612 Added 8.63%
385,461 $736,000
Q2 2022

Aug 15, 2022

SELL
$1.98 - $3.17 $24,433 - $39,117
-12,340 Reduced 3.36%
354,849 $962,000
Q1 2022

May 11, 2022

BUY
$2.42 - $3.98 $34,451 - $56,659
14,236 Added 4.03%
367,189 $1.09 Million
Q4 2021

Feb 11, 2022

BUY
$3.11 - $4.61 $298,659 - $442,707
96,032 Added 37.38%
352,953 $1.37 Million
Q3 2021

Nov 12, 2021

BUY
$2.65 - $4.62 $44,861 - $78,211
16,929 Added 7.05%
256,921 $1.1 Million
Q2 2021

Aug 11, 2021

BUY
$2.5 - $3.51 $471,440 - $661,901
188,576 Added 366.77%
239,992 $727,000
Q1 2021

May 13, 2021

SELL
$3.14 - $4.84 $15,379 - $23,706
-4,898 Reduced 8.7%
51,416 $171,000
Q4 2020

Feb 09, 2021

BUY
$2.76 - $4.97 $106,472 - $191,727
38,577 Added 217.49%
56,314 $199,000
Q3 2020

Nov 12, 2020

SELL
$1.75 - $6.2 $417,532 - $1.48 Million
-238,590 Reduced 93.08%
17,737 $55,000
Q3 2019

Nov 07, 2019

BUY
$1.34 - $2.4 $343,478 - $615,184
256,327 New
256,327 $392,000
Q2 2019

Aug 12, 2019

SELL
$1.46 - $4.44 $143,033 - $434,977
-97,968 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$3.41 - $4.57 $19,389 - $25,985
5,686 Added 6.16%
97,968 $350,000
Q4 2018

Feb 11, 2019

SELL
$3.5 - $9.66 $348,512 - $961,894
-99,575 Reduced 51.9%
92,282 $353,000
Q3 2018

Nov 09, 2018

BUY
$7.85 - $12.35 $850,924 - $1.34 Million
108,398 Added 129.88%
191,857 $0
Q2 2018

Aug 06, 2018

BUY
$5.0 - $7.35 $417,295 - $613,423
83,459 New
83,459 $609,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $513M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.